A Single Arm, Open Label Study of First Line Treatment With Tarceva Plus Avastin on Progression-free Survival in Patients With Advanced or Metastatic Liver Cancer.

Trial Profile

A Single Arm, Open Label Study of First Line Treatment With Tarceva Plus Avastin on Progression-free Survival in Patients With Advanced or Metastatic Liver Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 15 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jan 2010 Planned end date changed from 1 Oct 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Planned number of patients changed from 49 to 51 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top